Revealing the heterogeneity of treatment resistance in less‐defined subtype diffuse large B cell lymphoma patients by integrating programmed cell death patterns and liquid biopsy
Abstract Precision medicine in less‐defined subtype diffuse large B‐cell lymphoma (DLBCL) remains a challenge due to the heterogeneous nature of the disease. Programmed cell death (PCD) pathways are crucial in the advancement of lymphoma and serve as significant prognostic markers for individuals af...
Saved in:
Main Authors: | Wei Hua, Jie Liu, Yue Li, Hua Yin, Hao‐Rui Shen, Jia‐Zhu Wu, Yi‐Lin Kong, Bi‐Hui Pan, Jun‐Heng Liang, Li Wang, Jian‐Yong Li, Rui Gao, Jin‐Hua Liang, Wei Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Clinical and Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/ctm2.70150 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Relapse of Diffuse Large B‐Cell Lymphoma as Painless Masses in the Abdominal Wall Muscles: A Rare Case Report
by: Somar Mansour, et al.
Published: (2025-01-01) -
Myeloid-derived suppressor cells exhibit distinct characteristics in bone marrow and blood of individuals with diffuse large B-cell lymphoma
by: Paris Efstratiou, et al.
Published: (2025-01-01) -
Treatment of primary esophageal lymphomas: A review
by: Joe El Khoury, et al.
Published: (2025-02-01) -
Breast lymphomas: Clinical and pathological insights from a tertiary cancer care center in India
by: Neha Singh, et al.
Published: (2024-12-01) -
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma
by: Sayan Mullick Chowdhury, et al.
Published: (2025-01-01)